In 2017, China became the world's second-largest national pharmaceutical market, due to its aging population and rising medical needs. In its ongoing commitment to adapt to emerging trends in the pharmaceutical industry, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, has expanded its facility in Shanghai, China.
0 Comments Click here to read/write comments
Tags: Central Laboratory, Clinical Trial, Development, Science Education, Shanghai